The transformative potential of artificial intelligence (AI) within medical affairs has been widely discussed, yet, realising its real-world commercial value requires a pragmatic approach t
With the hype around generative AI (GenAI), there is an increasing demand to explore its capabilities across pharma and MedTech companies, as well as contract research organisations.
The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year